Subcutaneous versus intravenous nivolumab for renal cell carcinoma.
Albiges L, Bourlon MT, Chacón M, Cutuli HJ, Chuken YAL, Żurawski B, Mota JM, Magri I, Burotto M, Luz M, de Menezes J, Ruiz EPY, Fu S, Richardet M, Valderrama BP, Maruzzo M, Bracarda S, Breckenridge M, Vezina HE, Rathod D, Yu Z, Zhao Y, Dixon M, Perumal D, George S.
Albiges L, et al. Among authors: perumal d.
Ann Oncol. 2024 Sep 15:S0923-7534(24)03996-6. doi: 10.1016/j.annonc.2024.09.002. Online ahead of print.
Ann Oncol. 2024.
PMID: 39288844
Free article.